CN1976718B - 抗hpv16和hpv18和至少一种另外的选自hpv31、45或52的hpv类型的疫苗 - Google Patents

抗hpv16和hpv18和至少一种另外的选自hpv31、45或52的hpv类型的疫苗 Download PDF

Info

Publication number
CN1976718B
CN1976718B CN2005800195155A CN200580019515A CN1976718B CN 1976718 B CN1976718 B CN 1976718B CN 2005800195155 A CN2005800195155 A CN 2005800195155A CN 200580019515 A CN200580019515 A CN 200580019515A CN 1976718 B CN1976718 B CN 1976718B
Authority
CN
China
Prior art keywords
hpv
vlp
type
composition according
hpv16
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN2005800195155A
Other languages
English (en)
Chinese (zh)
Other versions
CN1976718A (zh
Inventor
S·德布鲁斯
M·-T·马丁
R·J·斯蒂芬
J·斯蒂芬尼
M·A·C·维滕多夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/114,301 external-priority patent/US20050287161A1/en
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Priority claimed from PCT/EP2005/006461 external-priority patent/WO2005123125A1/en
Publication of CN1976718A publication Critical patent/CN1976718A/zh
Application granted granted Critical
Publication of CN1976718B publication Critical patent/CN1976718B/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN2005800195155A 2004-06-16 2005-06-14 抗hpv16和hpv18和至少一种另外的选自hpv31、45或52的hpv类型的疫苗 Expired - Lifetime CN1976718B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0413510.9 2004-06-16
GBGB0413510.9A GB0413510D0 (en) 2004-06-16 2004-06-16 Vaccine
US11/114,301 US20050287161A1 (en) 2002-12-20 2005-04-26 Vaccine
US11/114,301 2005-04-26
PCT/EP2005/006461 WO2005123125A1 (en) 2004-06-16 2005-06-14 Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52

Publications (2)

Publication Number Publication Date
CN1976718A CN1976718A (zh) 2007-06-06
CN1976718B true CN1976718B (zh) 2012-10-10

Family

ID=32750044

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2005800195155A Expired - Lifetime CN1976718B (zh) 2004-06-16 2005-06-14 抗hpv16和hpv18和至少一种另外的选自hpv31、45或52的hpv类型的疫苗

Country Status (15)

Country Link
JP (1) JP2012102132A (enrdf_load_html_response)
KR (1) KR101359943B1 (enrdf_load_html_response)
CN (1) CN1976718B (enrdf_load_html_response)
CY (1) CY1113830T1 (enrdf_load_html_response)
DK (1) DK1758609T3 (enrdf_load_html_response)
ES (1) ES2394448T3 (enrdf_load_html_response)
GB (1) GB0413510D0 (enrdf_load_html_response)
HR (1) HRP20120930T1 (enrdf_load_html_response)
HU (3) HUS1500061I1 (enrdf_load_html_response)
LT (1) LTC1758609I2 (enrdf_load_html_response)
NL (3) NL300771I2 (enrdf_load_html_response)
PT (1) PT1758609E (enrdf_load_html_response)
SI (1) SI1758609T1 (enrdf_load_html_response)
TW (1) TW200612983A (enrdf_load_html_response)
ZA (1) ZA200610057B (enrdf_load_html_response)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2416798T3 (en) * 2009-04-10 2018-01-08 Univ Johns Hopkins PAPILLOMAVIRUS-LIKE PARTICLES (VLP) AS WIDE-SPECIFIED VACCINES AGAINST HUMAN PAPILLOMAVIRUS (HPV)
RU2013106498A (ru) * 2010-07-15 2014-08-20 Бритиш Коламбиа Кэнсер Эйдженси Бранч Антигенные композиции папилломавируса человека е7 и их применение
CN107188966B (zh) 2016-03-15 2020-03-31 中国医学科学院基础医学研究所 一种乳头瘤病毒嵌合蛋白及其用途
CN114539365B (zh) * 2020-11-26 2023-12-01 中国医学科学院基础医学研究所 一种改造的人乳头瘤病毒52型l1蛋白及其用途
CN114716560B (zh) 2021-01-04 2024-02-02 中国医学科学院基础医学研究所 一种人乳头瘤病毒18型嵌合蛋白及其用途
CN114716561B (zh) 2021-01-04 2024-03-12 中国医学科学院基础医学研究所 一种人乳头瘤病毒31型嵌合蛋白及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003077942A2 (en) * 2002-03-18 2003-09-25 Glaxosmithkline Biologicals Sa Virus-like particles of human papillomavirus

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9921147D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB0110431D0 (en) * 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
GB0206359D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003077942A2 (en) * 2002-03-18 2003-09-25 Glaxosmithkline Biologicals Sa Virus-like particles of human papillomavirus

Also Published As

Publication number Publication date
CN1976718A (zh) 2007-06-06
DK1758609T3 (da) 2012-12-10
LTC1758609I2 (lt) 2017-05-10
NL300774I1 (enrdf_load_html_response) 2015-12-29
TW200612983A (en) 2006-05-01
JP2012102132A (ja) 2012-05-31
HUS1500060I1 (hu) 2017-10-30
NL300771I1 (enrdf_load_html_response) 2015-12-29
NL300773I1 (enrdf_load_html_response) 2015-12-29
HUS1500059I1 (hu) 2017-10-30
HRP20120930T1 (hr) 2012-12-31
HUS1500061I1 (hu) 2016-01-28
SI1758609T1 (sl) 2013-01-31
NL300771I2 (enrdf_load_html_response) 2015-12-29
GB0413510D0 (en) 2004-07-21
ZA200610057B (en) 2008-02-27
NL300774I2 (enrdf_load_html_response) 2015-12-29
NL300773I2 (enrdf_load_html_response) 2015-12-29
ES2394448T3 (es) 2013-01-31
CY1113830T1 (el) 2016-06-22
KR101359943B1 (ko) 2014-02-10
PT1758609E (pt) 2012-12-21
KR20120123617A (ko) 2012-11-08

Similar Documents

Publication Publication Date Title
US20050287161A1 (en) Vaccine
US20110189229A1 (en) Vaccine against hpv
US20090181052A1 (en) Vaccine
JP2012102132A (ja) Ｈｐｖ１６およびｈｐｖ１８ならびにｈｐｖ３１、４５または５２から選ばれる少なくとも１つの別のｈｐｖ型に対するワクチン
EP1758609B1 (en) Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52
CN101217976A (zh) 疫苗
US7758866B2 (en) Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
US7858098B2 (en) Vaccine
CN101217975A (zh) 疫苗
CN100418577C (zh) Hpv-16和hpv-18l1vlp疫苗
CA2606206A1 (en) Vaccine
Mandić Prophylactic HPV vaccines
BRPI0610032A2 (pt) uso de uma proteìna l1 do papilomavìrus humano ou fragmento imunogêico da mesma de um primeiro tipo de hpv, programa de vacinação para proteção contra a infecção e/ou doença por hiv, método para prevenção da infecção e/ou doença por hpv, composição de vacina, e, kit
Viscidi et al. Cervarix
BRPI0610396A2 (pt) vacina de hpv multivalente, métodos para proteger um paciente contra a infecção, para prevenir ou reduzir a freqüênca de anormalidades citológicas em um paciente, para prevenir a formação de lesões cin histologicamente confirmadas e para fabricar a vacina, e, usos de uma composição, de uma vacina e de uma composição de vacina

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20121010